▲ ctDNA甲基化分析的主要两种方法 最后,需要提及的就是人工智能(AI)和机器学习(ML)对癌症中ctDNA甲基化模型的解码加持。成功的ctDNA甲基化生物标志物的开发需要特定的测试性能阈值和精确的临床效用。多年来,Laboratory for Advanced Medicine(LAM),Freenome,Grail 和 Exact Sciences 等公司一直在实施 AI 和 ML 算法,并利用数据科学的力量来识别和验证癌症特异性DNA甲基化标志。此外,AI 和 ML 的应用已经在基于液体活检的癌症护理中发挥着重要作用,并显著加快了分析大量数据的过程,以提供更快、更明智的决策。6
1.Pantel K & Alix-Panabières C (2010) Circulating tumour cells in cancer patients: challenges and perspectives. Trends Mol Med 16, 398–406.2.Gormally, E. et al (2006). TP53 and KRAS2 mutations in plasma DNA of healthy subjects and subsequent cancer occurrence: A prospective study Cancer Research, 66(13), 6871–6876. 3.Jones PA (2012) Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat Rev Genet 13, 484–492. 4.Phillips T. The role of methylation in gene expression. Nat. Educ. 2008;1:116. 5.Leygo C, Williams M, Jin HC. et al. DNA methylation as a noninvasive epigenetic biomarker for the detection of cancer. Dis Markers. 2017; 2017: 3726595.6.Holder LB, Haque MM, Skinner MK. Machine learning for epigenetics and future medical applications. Epigenetics. 2017;12(7):505–514. 7.Cheuk IW, Shin VY & Kwong A (2017) Detection of methylated circulating DNA as noninvasive biomarkers for breast cancer diagnosis. J Breast Cancer 20, 12– 19.8.Mijnes J, Tiedemann J, Eschenbruch J, Gasthaus J, Bringezu S, Bauerschlag D, Maass N, Arnold N, Weimer J, Anzeneder T et al. (2019) SNiPER: a novel hypermethylation biomarker panel for liquid biopsy based early breast cancer detection. Oncotarget 10, 6494– 6508.9.Salta S, Nunes P, Fontes-Sousa M, Lopes P, Freitas M, Caldas M, Antunes L, Castro F, Antunes P, Palma de Sousa S et al. (2018) A DNA methylation-based test for breast cancer detection in circulating cell-free DNA. J Clin Med 7, 420.10.Uehiro N, Sato F, Pu F, Tanaka S, Kawashima M, Kawaguchi K, Sugimoto M, Saji S & Toi M(2016) Circulating cell-free DNA-based epigenetic assay can detect early breast cancer. Breast Cancer Res 18, 129.11.Brait M, Banerjee M, Maldonado L, Ooki A, Loyo M, Guida E, Izumchenko E, Mangold L, Humphreys E, Rosenbaum E et al. (2017) Promoter methylation of MCAM, ERα and ERβ in serum of early stage prostate cancer patients. Oncotarget 8, 15431– 15440.12.Herman JG & Farooq M (2020) Noninvasive diagnostics for early detection of lung cancer: challenges and potential with a focus on changes in DNA methylation. Cancer Epidemiol Biomarkers Prev 29, 2416– 2422.13.Vrba L, Oshiro MM, Kim SS, Garland LL, Placencia C, Mahadevan D, Nelson MA & Futscher BW(2020) DNA methylation biomarkers discovered in silico detect cancer in liquid biopsies from non-small cell lung cancer patients. Epigenetics 15, 419– 430.14.Gallardo-Gómez M, Moran S, Páez de la Cadena M, Martínez-Zorzano VS, Rodríguez-Berrocal FJ, Rodríguez-Girondo M, Esteller M, Cubiella J, Bujanda L, Castells A et al. (2018) A new approach to epigenome-wide discovery of non-invasive methylation biomarkers for colorectal cancer screening in circulating cell-free DNA using pooled samples. Clin Epigenetics 10, 53.15.Wu X, Zhang Y, Hu T, et al. A novel cell-free DNA methylation-based model improves the early detection of colorectal cancer. Mol Oncol. 2021;15(10):2702-2714. 16.Petit J, Carroll G, Gould T, Pockney P, Dun M & Scott RJ (2018) Cell-free DNA as a diagnostic blood-based biomarker for colorectal cancer: a systematic review. J Surg Res 236, 184– 197.17.Worm Ørntoft MB (2018) Review of blood-based colorectal cancer screening: how far are circulating cell-free DNA methylation markers from clinical implementation? Clin Colorectal Cancer17, e415– e433.18.Danese E, Montagnana M & Lippi G (2019) Circulating molecular biomarkers for screening or early diagnosis of colorectal cancer: which is ready for prime time? Ann Transl Med 7, 610